Longeveron (LGVN) Change in Account Payables (2020 - 2026)
Longeveron's (LGVN) quarterly Change in Account Payables came in at -$130000.0 in Q1 2026, down 148.69% year-on-year from $267000.0 in Q1 2025, and up 80.18% quarter-over-quarter from -$656000.0 in Q4 2025.
Longeveron (LGVN) Change in Account Payables (2020 - 2026) Analysis & Trends
Longeveron's Change in Account Payables history runs 7 years deep, the most recent figure standing at -$130000.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables fell 148.69% year-over-year to -$130000.0 in Q1 2026; TTM through Mar 2026 was -$72000.0, a 93.47% increase from a year earlier, with the FY2025 full-year figure at $325000.0, up 160.19% from the prior year.
- Change in Account Payables rose to -$130000.0 in Q1 2026 per LGVN's latest filing, from -$656000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.2 million in Q2 2023 and bottomed at -$1.3 million in Q1 2023.
- The 5-year median for Change in Account Payables is -$7000.0 (2022), against an average of -$20705.9.
- Biggest YoY gain for Change in Account Payables was 631.2% in 2023; the steepest drop was 18385.71% in 2023.
- Year by year, Change in Account Payables stood at $1.1 million in 2022, then sank by 116.65% to -$191000.0 in 2023, then plunged by 312.57% to -$788000.0 in 2024, then advanced by 16.75% to -$656000.0 in 2025, then soared by 80.18% to -$130000.0 in 2026.
- Per Business Quant, the three latest LGVN Change in Account Payables figures stand at -$130000.0 (Q1 2026), -$656000.0 (Q4 2025), and $380000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 16.86 Mn |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 | -130,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -130,000.00 |
| Mar 31, 2026 | -130,000.00 |
| Dec 31, 2025 | -656,000.00 |
| Dec 31, 2025 | -656,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | 267,000.00 |
| Mar 31, 2025 | 267,000.00 |
| Dec 31, 2024 | -788,000.00 |
| Dec 31, 2024 | -788,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Jun 30, 2024 | -867,000.00 |
| Jun 30, 2024 | -867,000.00 |
| Mar 31, 2024 | 829,000.00 |
| Mar 31, 2024 | 829,000.00 |
| Dec 31, 2023 | -191,000.00 |
| Dec 31, 2023 | -191,000.00 |